2022 年 HIV-1 耐药突变更新。
2022 update of the drug resistance mutations in HIV-1.
机构信息
University Medical Center Utrecht, The Netherlands and Ezintsha, University of the Witwatersrand, Johannesburg, South Africa.
Pierre et Marie Curie University and Pitié-Salpêtrière Hospital, Paris, France.
出版信息
Top Antivir Med. 2022 Oct;30(4):559-574.
Abstract
The 2022 edition of the IAS-USA drug resistance mutations list updates the Figure last published in September 2019. The mutations listed are those that have been identified by specific criteria for evidence and drugs described. The Figure is designed to assist practitioners to identify key mutations associated with resistance to antiretroviral drugs, and therefore, in making clinical decisions regarding antiretroviral therapy.
摘要
2022 年版的 IAS-USA 耐药突变列表更新了最后一次发布于 2019 年 9 月的图表。列表中的突变是根据证据和描述的药物的具体标准确定的。该图表旨在帮助临床医生识别与抗逆转录病毒药物耐药相关的关键突变，从而做出抗逆转录病毒治疗的临床决策。
相似文献
1
2022 update of the drug resistance mutations in HIV-1.2022 年 HIV-1 耐药突变更新。
Top Antivir Med. 2022 Oct;30(4):559-574.
2
2019 update of the drug resistance mutations in HIV-1.2019年人类免疫缺陷病毒1型耐药性突变的更新情况。
Top Antivir Med. 2019 Sep;27(3):111-121.
3
2015 Update of the Drug Resistance Mutations in HIV-1.《2015年HIV-1耐药性突变更新》
Top Antivir Med. 2015 Oct-Nov;23(4):132-41.
4
Update of the Drug Resistance Mutations in HIV-1: 2005.2005年HIV-1耐药性突变的更新情况。
Top HIV Med. 2005 Mar-Apr;13(1):51-7.
5
Update of the drug resistance mutations in HIV-1: Fall 2005.2005年秋季HIV-1耐药性突变的更新情况。
Top HIV Med. 2005 Oct-Nov;13(4):125-31.
6
2017 Update of the Drug Resistance Mutations in HIV-1.《2017年HIV-1耐药性突变更新》
Top Antivir Med. 2016 Dec;24(4):132-133.
7
Update of the drug resistance mutations in HIV-1: Fall 2006.2006年秋季HIV-1耐药性突变更新
Top HIV Med. 2006 Aug-Sep;14(3):125-30.
8
Update of the Drug Resistance Mutations in HIV-1.人类免疫缺陷病毒1型耐药突变的更新
Top HIV Med. 2008 Dec;16(5):138-45.
9
2014 Update of the drug resistance mutations in HIV-1.2014年人类免疫缺陷病毒1型耐药性突变更新
Top Antivir Med. 2014 Jun-Jul;22(3):642-50.
10
2011 update of the drug resistance mutations in HIV-1.2011年人类免疫缺陷病毒1型耐药性突变的更新情况
Top Antivir Med. 2011 Nov;19(4):156-64.
引用本文的文献
1
Synthesis of novel N1 functionalized diazepinone analogues a base-mediated C-N cross coupling reaction as reverse transcriptase inhibitors: theoretical and experimental investigations.新型N1官能化二氮杂䓬酮类似物的合成——作为逆转录酶抑制剂的碱介导C-N交叉偶联反应：理论与实验研究
RSC Adv. 2025 Aug 18;15(36):29160-29175. doi: 10.1039/d5ra03504j.
2
Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data.简短报告：对同时感染HIV-1和乙型肝炎且开始使用比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺或多替拉韦联合恩曲他滨/富马酸替诺福韦二吡呋酯进行治疗的参与者的HIV-1耐药性分析：ALLIANCE数据的亚组分析
J Acquir Immune Defic Syndr. 2024 Aug 1;96(4):380-384. doi: 10.1097/QAI.0000000000003434. Epub 2024 Jun 21.
3
Mechanisms of Immune Evasion in HIV-1: The Role of Virus-Host Protein Interactions.HIV-1免疫逃逸机制：病毒-宿主蛋白相互作用的作用
Curr Issues Mol Biol. 2025 May 16;47(5):367. doi: 10.3390/cimb47050367.
4
Unique molecular signatures in rebound viruses from antiretroviral drug and CRISPR-treated HIV-1-infected humanized mice.来自接受抗逆转录病毒药物和CRISPR治疗的HIV-1感染人源化小鼠的反弹病毒中的独特分子特征。
Commun Biol. 2025 Jul 19;8(1):1077. doi: 10.1038/s42003-025-08499-6.
5
Advances in HIV Treatment and Vaccine Development: Emerging Therapies and Breakthrough Strategies for Long-Term Control.艾滋病治疗与疫苗研发进展：新兴疗法及长期控制的突破性策略
AIDS Res Treat. 2025 Jul 4;2025:6829446. doi: 10.1155/arat/6829446. eCollection 2025.
6
Clinical and Health Care Resource Use Outcomes Associated With Resistance to Antiretroviral Therapy Among Veterans With HIV.感染艾滋病毒退伍军人中与抗逆转录病毒疗法耐药性相关的临床及医疗保健资源使用结果
Open Forum Infect Dis. 2025 Jun 9;12(7):ofaf340. doi: 10.1093/ofid/ofaf340. eCollection 2025 Jul.
7
Integrative Computational Approaches for Understanding Drug Resistance in HIV-1 Protease Subtype C.用于理解HIV-1蛋白酶C亚型耐药性的综合计算方法
Viruses. 2025 Jun 16;17(6):850. doi: 10.3390/v17060850.
8
Strategies and efforts in circumventing the emergence of antiviral resistance against conventional antivirals.规避传统抗病毒药物出现耐药性的策略与努力。
NPJ Antimicrob Resist. 2025 Jun 9;3(1):54. doi: 10.1038/s44259-025-00125-z.
9
Evolutionary Sequence and Structural Basis for the Epistatic Origins of Drug Resistance in HIV.HIV耐药性上位起源的进化序列与结构基础
bioRxiv. 2025 May 2:2025.04.30.651576. doi: 10.1101/2025.04.30.651576.
10
Treatment of Advanced HIV in the Modern Era.现代时代晚期HIV的治疗
Drugs. 2025 May 12. doi: 10.1007/s40265-025-02181-1.
本文引用的文献
1
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.利纳卡帕韦治疗多种药物耐药 HIV-1 感染时对衣壳的抑制作用。
N Engl J Med. 2022 May 12;386(19):1793-1803. doi: 10.1056/NEJMoa2115542.
2
Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study.临床观察到的 HIV 整合酶突变组合对整合酶链转移抑制剂（INSTIs）表型耐药性的影响：一项分子研究。
J Antimicrob Chemother. 2022 Mar 31;77(4):979-988. doi: 10.1093/jac/dkab498.
3
Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study.在一项概念验证临床研究中对 lenacapavir 的表型耐药性和单药疗效。
J Antimicrob Chemother. 2022 Mar 31;77(4):989-995. doi: 10.1093/jac/dkab503.
4
Lenacapavir: a first-in-class HIV-1 capsid inhibitor.来那卡帕韦：一种一流的HIV-1衣壳抑制剂。
Curr Opin HIV AIDS. 2022 Jan 1;17(1):15-21. doi: 10.1097/COH.0000000000000713.
5
Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc.替诺福韦与依非韦伦或马拉韦罗无交叉耐药的临床证据。
AIDS. 2022 Jan 1;36(1):11-18. doi: 10.1097/QAD.0000000000003097.
6
Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.多替拉韦或达芦那韦联合齐多夫定或替诺福韦治疗HIV
N Engl J Med. 2021 Jul 22;385(4):330-341. doi: 10.1056/NEJMoa2101609.
7
Case Report: Emergent Resistance in a Treatment-Naive Person With Human Immunodeficiency Virus Under Bictegravir-Based Therapy.病例报告：初治的人类免疫缺陷病毒感染者在基于比克替拉韦的治疗下出现紧急耐药
Open Forum Infect Dis. 2021 Jun 4;8(6):ofab297. doi: 10.1093/ofid/ofab297. eCollection 2021 Jun.
8
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.接受注射用卡博特韦预防艾滋病毒的男同性恋和顺性别男性及跨性别女性中人类免疫缺陷病毒（HIV）感染的特征：HPTN 083研究
J Infect Dis. 2021 Nov 16;224(9):1581-1592. doi: 10.1093/infdis/jiab152.
9
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.探索长效卡替拉韦和利匹韦林治疗 HIV-1 病毒学失败的预测因素：多变量分析。
AIDS. 2021 Jul 15;35(9):1333-1342. doi: 10.1097/QAD.0000000000002883.
10
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.长效卡博特韦和利匹韦林每 2 个月给药 1 次用于治疗 HIV-1 感染成人（ATLAS-2M）：48 周结果：一项随机、多中心、开放标签、3b 期、非劣效性研究。
Lancet. 2021 Dec 19;396(10267):1994-2005. doi: 10.1016/S0140-6736(20)32666-0. Epub 2020 Dec 9.
Zotero 插件